

Tobias Feuchtinger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6471633/publications.pdf>

Version: 2024-02-01

136
papers

5,198
citations

101543

36
h-index

91884

69
g-index

139
all docs

139
docs citations

139
times ranked

5894
citing authors

#	ARTICLE	IF	CITATIONS
1	Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. <i>Blood</i> , 2010, 116, 4360-4367.	1.4	409
2	Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. <i>British Journal of Haematology</i> , 2006, 134, 64-76.	2.5	368
3	The extended phenotype of LPS-responsive beige-like anchor protein (LRBA) deficiency. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 223-230.	2.9	247
4	Adoptive Transfer of Epstein-Barr Virus (EBV) Nuclear Antigen 1â€“Specific T Cells As Treatment for EBV Reactivation and Lymphoproliferative Disorders After Allogeneic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2013, 31, 39-48.	1.6	237
5	European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: summary of <sc>ECIL</sc>â€“4 (2011). <i>Transplant Infectious Disease</i> , 2012, 14, 555-563.	1.7	224
6	Improved immune recovery after transplantation of TCRÎ±Î²/CD19-depleted allografts from haploidentical donors in pediatric patients. <i>Bone Marrow Transplantation</i> , 2015, 50, S6-S10.	2.4	145
7	T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts. <i>Oncotarget</i> , 2016, 7, 76902-76919.	1.8	131
8	Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT. <i>Blood</i> , 2015, 125, 1986-1994.	1.4	127
9	Depletion of T-cell receptor alpha/beta and CD19 positive cells from apheresis products with the CliniMACS device. <i>Cytotherapy</i> , 2013, 15, 1253-1258.	0.7	125
10	Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab. <i>Haematologica</i> , 2014, 99, 1212-1219.	3.5	125
11	Induction of a central memory and stem cell memory phenotype in functionally active CD4+ and CD8+ CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19+ acute lymphoblastic leukemia. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1053-1066.	4.2	116
12	Strategies of adoptive T-cell transfer to treat refractory viral infections post allogeneic stem cell transplantation. <i>Journal of Hematology and Oncology</i> , 2019, 12, 13.	17.0	111
13	Transplantation of <sc>CD</sc>3/<sc>CD</sc>19 depleted allografts from haploidentical family donors in paediatric leukaemia. <i>British Journal of Haematology</i> , 2014, 165, 688-698.	2.5	109
14	Isolation and expansion of human adenovirusâ€“specific CD4+ and CD8+ T cells according to IFN-Î³ secretion for adjuvant immunotherapy. <i>Experimental Hematology</i> , 2004, 32, 282-289.	0.4	105
15	Detection of adenovirus-specific T cells in children with adenovirus infection after allogeneic stem cell transplantation. <i>British Journal of Haematology</i> , 2005, 128, 503-509.	2.5	101
16	Long-term outcome after haploidentical stem cell transplantation in children. <i>Blood Cells, Molecules, and Diseases</i> , 2004, 33, 281-287.	1.4	99
17	Pneumococcal conjugate vaccine provides early protective antibody responses in children after related and unrelated allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2007, 109, 2322-2326.	1.4	97
18	Clinical Grade Generation of Hexon-specific T Cells for Adoptive T-cell Transfer as a Treatment of Adenovirus Infection After Allogeneic Stem Cell Transplantation. <i>Journal of Immunotherapy</i> , 2008, 31, 199-206.	2.4	96

#	ARTICLE	IF	CITATIONS
19	Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR. <i>Blood</i> , 2020, 136, 1407-1418.	1.4	91
20	Transplantation of a combination of CD133 ⁺ and CD34 ⁺ selected progenitor cells from alternative donors. <i>British Journal of Haematology</i> , 2004, 124, 72-79.	2.5	86
21	Haploidentical Stem Cell Transplantation in Patients with Pediatric Solid Tumors: Preliminary Results of a Pilot Study and Analysis of Graft versus Tumor Effects. <i>Klinische Padiatrie</i> , 2006, 218, 321-326.	0.6	79
22	Reconstitution of natural killer cell receptors influences natural killer activity and relapse rate after haploidentical transplantation of T- and B-cell depleted grafts in children. <i>Haematologica</i> , 2010, 95, 1381-1388.	3.5	79
23	Outcome of hematopoietic cell transplantation for DNA double-strand break repair disorders. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 322-328.e10.	2.9	79
24	A Comparison between Three Graft Manipulation Methods for Haploidentical Stem Cell Transplantation in Pediatric Patients: Preliminary Results of a Pilot Study. <i>Klinische Padiatrie</i> , 2005, 217, 334-338.	0.6	76
25	Adenovirus infection after allogeneic stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2007, 48, 244-255.	1.3	72
26	Feasibility and Outcome of Reduced-Intensity Conditioning in Haploidentical Transplantation. <i>Annals of the New York Academy of Sciences</i> , 2007, 1106, 279-289.	3.8	66
27	Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors. <i>Science Advances</i> , 2021, 7, .	10.3	56
28	Haploidentical Stem Cell Transplantation for Refractory/Relapsed Neuroblastoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1005-1012.	2.0	55
29	Chimeric CD19 antibody mediates cytotoxic activity against leukemic blasts with effector cells from pediatric patients who received T-cell-depleted allografts. <i>Blood</i> , 2004, 103, 3982-3985.	1.4	53
30	Immune reconstitution and strategies for rebuilding the immune system after haploidentical stem cell transplantation. <i>Annals of the New York Academy of Sciences</i> , 2012, 1266, 161-170.	3.8	51
31	Viral Infections in Immunocompromised Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, S2-S5.	2.0	50
32	Monocyte-Induced Development of Th17 Cells and the Release of S100 Proteins Are Involved in the Pathogenesis of Graft-versus-Host Disease. <i>Journal of Immunology</i> , 2014, 193, 3355-3365.	0.8	49
33	CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy. <i>Blood</i> , 2021, 137, 1037-1049.	1.4	45
34	Immunological long-term follow-up of neuroblastoma stage IV patients after anti-GD2 CH14.18 antibody treatment.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3029-3029.	1.6	45
35	Intensity of HLA class I expression and KIR-mismatch determine NK-cell mediated lysis of leukaemic blasts from children with acute lymphatic leukaemia. <i>British Journal of Haematology</i> , 2007, 138, 97-100.	2.5	42
36	Human MLL/KMT2A gene exhibits a second breakpoint cluster region for recurrent MLL-USP2 fusions. <i>Leukemia</i> , 2019, 33, 2306-2340.	7.2	41

#	ARTICLE	IF	CITATIONS
37	CD34 ⁺ selected stem cell boosts can improve poor graft function after paediatric allogeneic stem cell transplantation. <i>British Journal of Haematology</i> , 2018, 180, 90-99.	2.5	39
38	Flow cytometry with anti HLA-antibodies: a simple but highly sensitive method for monitoring chimerism and minimal residual disease after HLA-mismatched stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2007, 39, 767-773.	2.4	38
39	Chronic graft-versus-host-disease in CD34 ⁺ -humanized NSG mice is associated with human susceptibility HLA haplotypes for autoimmune disease. <i>Journal of Autoimmunity</i> , 2015, 62, 55-66.	6.5	38
40	Blinatumomab in pediatric patients with relapsed/refractory B ϵ cell precursor acute lymphoblastic leukemia. <i>European Journal of Haematology</i> , 2021, 106, 473-483.	2.2	38
41	Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1281-1292.	2.5	35
42	T-cell replete haploidentical bone marrow transplantation and post-transplant cyclophosphamide for patients with inborn errors. <i>Haematologica</i> , 2019, 104, e478-e482.	3.5	34
43	Adenoviral Infections after Transplantation of Positive Selected Stem Cells from Haploidentical Donors in Children: An Update. <i>Klinische Padiatrie</i> , 2005, 217, 339-344.	0.6	33
44	Adoptive T Cell Therapy Strategies for Viral Infections in Patients Receiving Haematopoietic Stem Cell Transplantation. <i>Cells</i> , 2019, 8, 47.	4.1	32
45	Leukemia-induced dysfunctional TIM-3 ⁺ CD4 ⁺ bone marrow T cells increase risk of relapse in pediatric B-precursor ALL patients. <i>Leukemia</i> , 2020, 34, 2607-2620.	7.2	31
46	Targeted T ϵ cell receptor gene editing provides predictable T ϵ cell product function for immunotherapy. <i>Cell Reports Medicine</i> , 2021, 2, 100374.	6.5	30
47	Treatment of graft failure with ϵ -based reconditioning and haploidentical stem cells in paediatric patients. <i>British Journal of Haematology</i> , 2016, 175, 115-122.	2.5	29
48	Reduced toxicity, myeloablative HLA-haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for sickle cell disease. <i>Annals of Hematology</i> , 2017, 96, 1373-1377.	1.8	26
49	Rituximab mediates in vitro antileukemic activity in pediatric patients after allogeneic transplantation. <i>Bone Marrow Transplantation</i> , 2005, 36, 91-97.	2.4	25
50	Cytolytic activity of NK cell clones against acute childhood precursor-B-cell leukaemia is influenced by HLA class I expression on blasts and the differential KIR phenotype of NK clones. <i>Bone Marrow Transplantation</i> , 2009, 43, 875-881.	2.4	25
51	Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy. <i>Cytotherapy</i> , 2019, 21, 973-986.	0.7	25
52	Association between adenovirus viral load and mortality in pediatric allo-HCT recipients: the multinational AdvAnce study. <i>Bone Marrow Transplantation</i> , 2019, 54, 1632-1642.	2.4	25
53	Determination of residual T- and B-cell content after immunomagnetic depletion: proposal for flow cytometric analysis and results from 103 separations. <i>Cytotherapy</i> , 2006, 8, 465-472.	0.7	23
54	Natural killer cell activity influences outcome after T cell depleted stem cell transplantation from matched unrelated and haploidentical donors. <i>Best Practice and Research in Clinical Haematology</i> , 2011, 24, 403-411.	1.7	22

#	ARTICLE	IF	CITATIONS
55	Rapid generation of NY-ESO-1-specific CD4 ⁺ T _H 1 cells for adoptive T-cell therapy. <i>Oncolmmunology</i> , 2015, 4, e1002723.	4.6	20
56	Treatment with omalizumab normalizes the number of myeloid dendritic cells during the grass pollen season. <i>Journal of Allergy and Clinical Immunology</i> , 2003, 111, 428-430.	2.9	19
57	Adoptive T-cell Transfer for Refractory Viral Infections with Cytomegalovirus, Epstein-Barr Virus or Adenovirus after Allogeneic Stem Cell Transplantation. <i>Klinische Padiatrie</i> , 2013, 225, 164-169.	0.6	19
58	Results of CoALL 07-03 study childhood ALL based on combined risk assessment by in vivo and in vitro pharmacosensitivity. <i>Blood Advances</i> , 2019, 3, 3688-3699.	5.2	19
59	Ex vivo detection of adenovirus specific CD4 ⁺ T-cell responses to HLA-DR-epitopes of the Hexon protein show a contracted specificity of T _H 1 cells following stem cell transplantation. <i>Virology</i> , 2010, 397, 277-284.	2.4	18
60	Dendritic cell vaccination in an allogeneic stem cell recipient receiving a transplant from a human cytomegalovirus (HCMV)-seronegative donor: induction of a HCMV-specific T _H 1 cell response. <i>Cytotherapy</i> , 2010, 12, 945-950.	0.7	18
61	Reduction of Minimal Residual Disease in Pediatric B-lineage Acute Lymphoblastic Leukemia by an Fc-optimized CD19 Antibody. <i>Molecular Therapy</i> , 2016, 24, 1634-1643.	8.2	18
62	The role of haematopoietic stem cell transplantation for sickle cell disease in the era of targeted disease-modifying therapies and gene editing. <i>Lancet Haematology</i> , 2020, 7, e902-e911.	4.6	18
63	Cellular Immune Reconstitution after Haploidentical Transplantation in Children. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 59-65.	2.0	17
64	Long-term IL-2 therapy after transplantation of T cell depleted stem cells from alternative donors in children. <i>Best Practice and Research in Clinical Haematology</i> , 2011, 24, 443-452.	1.7	17
65	Identification of a Novel Immunodominant HLA-B*07. <i>Journal of Immunotherapy</i> , 2015, 38, 267-275.	2.4	17
66	Posaconazole plasma concentration in pediatric patients receiving antifungal prophylaxis after allogeneic hematopoietic stem cell transplantation. <i>Medical Mycology</i> , 2016, 54, 128-137.	0.7	17
67	CRISPR-Cas9-Mediated Glucocorticoid Resistance in Virus-Specific T Cells for Adoptive T Cell Therapy Posttransplantation. <i>Molecular Therapy</i> , 2020, 28, 1965-1973.	8.2	17
68	Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteins. <i>Blood Cancer Journal</i> , 2021, 11, 108.	6.2	17
69	MRD response in a refractory paediatric T-ALL patient through anti-programmed cell death 1 (PD-1) Ab treatment associated with induction of fatal GvHD. <i>Bone Marrow Transplantation</i> , 2017, 52, 1221-1224.	2.4	16
70	Systematic identification of cancer-specific MHC-binding peptides with RAVEN. <i>Oncolmmunology</i> , 2018, 7, e1481558.	4.6	16
71	Presence of centromeric but absence of telomeric group B KIR haplotypes in stem cell donors improve leukaemia control after HSCT for childhood ALL. <i>Bone Marrow Transplantation</i> , 2019, 54, 1847-1858.	2.4	16
72	Five donors to one recipient: modeling a mosaic of granulocytes, natural killer and T cells from cord-blood and third-party donors. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 291-295.	4.3	15

#	ARTICLE	IF	CITATIONS
73	Favorable NK cell activity after haploidentical hematopoietic stem cell transplantation in stage IV relapsed Ewingâ€™s sarcoma patients. <i>Bone Marrow Transplantation</i> , 2015, 50, S72-S76.	2.4	15
74	Outcomes of pediatric identical livingâ€™donor liver and hematopoietic stem cell transplantation. <i>Pediatric Transplantation</i> , 2016, 20, 888-897.	1.0	15
75	Dynamics of the Emergence of a Human Cytomegalovirus UL97 Mutant Strain Conferring Ganciclovir Resistance in a Pediatric Stem-Cell Transplant Recipient. <i>Journal of Molecular Diagnostics</i> , 2009, 11, 364-368.	2.8	13
76	Posaconazole plasma concentrations in pediatric patients receiving antifungal prophylaxis during neutropenia. <i>Medical Mycology</i> , 2016, 55, myw091.	0.7	13
77	Ferritin as an early marker of graft rejection after allogeneic hematopoietic stem cell transplantation in pediatric patients. <i>Annals of Hematology</i> , 2016, 95, 311-323.	1.8	13
78	Consensus of German Transplant Centers on Hematopoietic Stem Cell Transplantation in Fanconi Anemia. <i>Klinische Padiatrie</i> , 2015, 227, 157-165.	0.6	11
79	CD3/CD19 Depleted Grafts for Haploidentical Stem Cell Transplantation in Children: Results of a Pilot Study.. <i>Blood</i> , 2006, 108, 3121-3121.	1.4	11
80	Antiviral activity against CMV-infected fibroblasts in pediatric patients transplanted with CD34+-selected allografts from alternative donors. <i>Human Immunology</i> , 2004, 65, 423-431.	2.4	10
81	Alloreactivity of Natural Killer Cell Clones Against Childhood Precursor-B Lymphoblastic Leukemia Cells Is Determined by Differential KIR Expression.. <i>Blood</i> , 2006, 108, 3691-3691.	1.4	10
82	Defined Central Memory and Stem Memory T Cell Phenotype of CD4 and CD8 CAR T Cells for the Treatment of CD19+ Acute Lymphoblastic Leukemia in an Automated Closed System. <i>Blood</i> , 2016, 128, 4558-4558.	1.4	9
83	Multimodal Treatment of Nasopharyngeal Carcinoma in Children, Adolescents and Young Adults-Extended Follow-Up of the NPC-2003-GPOH Study Cohort and Patients of the Interim Cohort. <i>Cancers</i> , 2022, 14, 1261.	3.7	9
84	Long-Term Remission After First-Line Single-Agent Treatment with Arsenic Trioxide of Relapsed Acute Promyelocytic Leukemia in an 8-Year-Old Boy. <i>Pediatric Hematology and Oncology</i> , 2011, 28, 334-337.	0.8	8
85	Daunorubicin during delayed intensification decreases the incidence of infectious complications â€“ a randomized comparison in trial CoALL 08-09. <i>Leukemia and Lymphoma</i> , 2019, 60, 60-68.	1.3	8
86	Design and Evaluation of TIM-3-CD28 Checkpoint Fusion Proteins to Improve Anti-CD19 CAR T-Cell Function. <i>Frontiers in Immunology</i> , 2022, 13, 845499.	4.8	8
87	Dendritic cells are susceptible to infection with wild-type adenovirus, inducing a differentiation arrest in precursor cells and inducing a strong T-cell stimulation. <i>Journal of General Virology</i> , 2010, 91, 1150-1154.	2.9	7
88	Children with Relapsed or Refractory Nephroblastoma: Favorable Long-term Survival after High-dose Chemotherapy and Autologous Stem Cell Transplantation. <i>Klinische Padiatrie</i> , 2014, 226, 351-356.	0.6	7
89	Leukemia escape in immune desert: intraocular relapse of pediatric pro-B-ALL during systemic control by CD19-CAR T cells. , 2020, 8, e001052.		7
90	Venetoclax and decitabine for relapsed paediatric myelodysplastic syndromeâ€™related acute myeloid leukaemia with complex aberrant karyotype after second stem cell transplantation. <i>British Journal of Haematology</i> , 2020, 189, e251-e254.	2.5	7

#	ARTICLE	IF	CITATIONS
91	Induction of Thelper1-driven Antiviral T-cell Lines for Adoptive Immunotherapy Is Determined by Differential Expression of IFN- γ and T-cell Activation Markers. <i>Journal of Immunotherapy</i> , 2012, 35, 661-669.	2.4	6
92	Anti-leukaemic activity of a novel haploidentical transplantation approach employing unmanipulated bone marrow followed by CD γ depleted peripheral blood stem cells in children with refractory/relapsed acute leukaemia. <i>British Journal of Haematology</i> , 2013, 162, 802-807.	2.5	6
93	Health-Related Physical Fitness and Arterial Stiffness in Childhood Cancer Survivors. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 63.	2.4	6
94	Haploidentical stem cell transplantation and subsequent immunotherapy with antiGD2 antibody for patients with relapsed metastatic neuroblastoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 10056-10056.	1.6	6
95	Analysis of self-reported activities of daily living, motor performance and physical activity among children and adolescents with cancer: Baseline data from a randomised controlled trial assessed shortly after diagnosis of leukaemia or non-Hodgkin lymphoma. <i>European Journal of Cancer Care</i> , 2022, 31, e13559.	1.5	6
96	Ex vivo expansion of autologous, donor-derived NK-, γ T-, and cytokine induced killer (CIK) cells post haploidentical hematopoietic stem cell transplantation results in increased antitumor activity. <i>Bone Marrow Transplantation</i> , 2019, 54, 727-732.	2.4	5
97	Anti-CD19 CARs displayed at the surface of lentiviral vector particles promote transduction of target-expressing cells. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 21, 42-53.	4.1	5
98	Genome-wide off-target analyses of CRISPR/Cas9-mediated T cell receptor engineering in primary human T cells. <i>Clinical and Translational Immunology</i> , 2022, 11, e1372.	3.8	5
99	Clofarabine increases the eradication of minimal residual disease of primary B-precursor acute lymphoblastic leukemia compared to high-dose cytarabine without improvement of outcome. Results from the randomized clinical trial 08-09 of the Cooperative Acute Lymphoblastic Leukemia Study Group. <i>Haematologica</i> , 2022, 107, 1026-1033.	3.5	4
100	Favorable immune recovery and low rate of GvHD in children transplanted with partially T cell-depleted PBSC grafts. <i>Bone Marrow Transplantation</i> , 2019, 54, 53-62.	2.4	3
101	Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy – results of a non-interventional observation study. <i>BMC Cancer</i> , 2019, 19, 1118.	2.6	3
102	CMV: persistent nemesis for SCT. <i>Blood</i> , 2016, 127, 2368-2369.	1.4	2
103	Protective T cell receptor identification for orthotopic reprogramming of immunity in refractory virus infections. <i>Molecular Therapy</i> , 2022, 30, 198-208.	8.2	2
104	T-cell immunity: strength out of quiescence?. <i>Blood</i> , 2017, 129, 663-664.	1.4	1
105	KTE-C19 (anti-CD19 chimeric antigen receptor [CAR] T cell therapy) in pediatric and adolescent patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL): Preliminary Results of ZUMA-4. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S252-S253.	0.4	1
106	<p>Antiemetic Prophylaxis with Fosaprepitant and 5-HT γ -Receptor Antagonists in Pediatric Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation</p>. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 3915-3927.	4.3	1
107	Identification of Predictive Markers of Severe and Prolonged Neutropenia after CD19-Specific CAR T-Cell Treatment in Patients with Relapsed/Refractory B-Cell Malignancies. <i>Blood</i> , 2020, 136, 41-42.	1.4	1
108	Transplantation Of TcR γ /CD19 Depleted Stem Cells From Haploidentical Donors In Children: Current Results. <i>Blood</i> , 2013, 122, 692-692.	1.4	1

#	ARTICLE	IF	CITATIONS
109	Leukemia Related Co-Stimulation / Co-Inhibition Predict T-Cell Attack of Acute Lymphoblastic Leukemia Mediated By Blinatumomab. <i>Blood</i> , 2015, 126, 3764-3764.	1.4	1
110	Adoptive Transfer of Hexon-Specific T-Cells as a Treatment of Adenovirus Reactivation Following Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2009, 114, 796-796.	1.4	1
111	Immunological recovery following HLA-matched CD3+ TCR ⁺ /CD19+ depleted hematopoietic stem cell transplantation in children. <i>Pediatric Transplantation</i> , 2022, , e14285.	1.0	1
112	The Potential Role of Natural Killer Cells in the Treatment of Malignant Disease. , 2008, , 352-362.		0
113	Susceptibility to childhood leukemia. <i>Blood</i> , 2011, 118, 1189-1190.	1.4	0
114	Differential expression of T _H 1 cytokines upon antigen stimulation predicts <i>in vivo</i> proliferative potential and cytokine production of virus-specific T cells following re-stimulation. <i>Transplant Infectious Disease</i> , 2014, 16, 713-723.	1.7	0
115	Transplantation of Haploidentical CD3/CD19 Depleted Stem Cells in Children: Final Results of a Multicenter Phase I/II Study. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S62.	2.0	0
116	T-Cell Replete Haploidentical Bone Marrow Transplantation and Post-Transplant Cyclophosphamide for Patients with Inborn Errors. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S212.	2.0	0
117	Improved Immune Reconstitution with Low Incidence of Severe Graft-Versus-Host Disease after Transplantation of CD34+ or CD133+ Enriched Stem Cells with Add-Back of Ten Million T-Cells Per Kg.. <i>Blood</i> , 2004, 104, 1239-1239.	1.4	0
118	Transplantation of Positive Selected Peripheral Stem Cells with Add-Back of T Cells from Unrelated Donors in Children: Favourable Survival and Low Incidence of GvHD.. <i>Blood</i> , 2006, 108, 2900-2900.	1.4	0
119	Quantitative HLA Class I Expression and KIR-Mismatch between NK-Cell-Donor and Patient Predict NK Cell Mediated Lysis of Leukemic Cells from Children with Acute Lymphatic Leukemia.. <i>Blood</i> , 2006, 108, 5205-5205.	1.4	0
120	Hexon Specific T-Cells for Adoptive T-Cell Transfer as a Treatment of Adenovirus Infection after Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2006, 108, 2853-2853.	1.4	0
121	Co-Transfusion of Donor NK Cells in Haploidentical Stem Cell Transplantation. <i>Blood</i> , 2008, 112, 2907-2907.	1.4	0
122	Long Term Survival and Relapse Rate After Transplantation of Highly T and B Cell Depleted Stem Cells From Alternative Donors in Pediatric Patients with Acute Lymphatic Leukemia.. <i>Blood</i> , 2009, 114, 4333-4333.	1.4	0
123	Improved T Cell Recovery After Transplantation of CD3/CD19 depleted Haploidentical Stem Cell Grafts in Pediatric Patients.. <i>Blood</i> , 2009, 114, 4652-4652.	1.4	0
124	Reduced Risk of Relapse In Pediatric ALL After Haploidentical Transplantation of T-Cell Depleted Grafts From KIR Haplotype B Donors.. <i>Blood</i> , 2011, 118, 4133-4133.	1.4	0
125	Involvement Of S100 Proteins and Hsp90 In The Pathogenesis Of Graft-Versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2013, 122, 2058-2058.	1.4	0
126	NY-ESO-1 specific CD4 ⁺ T _H 1 cells for immunotherapy of cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3071-3071.	1.6	0

#	ARTICLE	IF	CITATIONS
127	Senescence induction in human melanoma by the combined action of type II interferon and tumor necrosis factor.. Journal of Clinical Oncology, 2014, 32, e22213-e22213.	1.6	0
128	Improved Immune Recovery after Transplantation of TCR $\alpha\beta$ /CD19 Depleted Allografts from Haploidentical Donors in Pediatric Patients. Blood, 2014, 124, 852-852.	1.4	0
129	Generation of specific polyclonal and polyfunctional CD4 ⁺ T-helper1 cells against WT-1, MAGE-A3, Survivin and ROR-1 for adoptive T-cell immunotherapy.. Journal of Clinical Oncology, 2015, 33, e14025-e14025.	1.6	0
130	Pharmacokinetic Analysis during Antifungal Prophylaxis with Posaconazole Suspension in Pediatric and Adolescent Patients after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2015, 126, 4338-4338.	1.4	0
131	Bone Marrow T Cells Are Driven into Exhaustion By Acute Leukemia in Pediatric Patients Based on Protein and Transcriptome Analysis. Blood, 2018, 132, 3722-3722.	1.4	0
132	TIM-3 Expression on CD4+ Bone Marrow T Cells Predicts Relapse of Pediatric B-Precursor Acute Lymphoblastic Leukemia. Blood, 2018, 132, 2833-2833.	1.4	0
133	Abstract A043: Anti-CD19 CAR T-cells with a CRISPR/Cas9-mediated T-cell receptor knockout show high functionality in the absence of alloreactivity in vitro. , 2019, , .		0
134	Abstract A224: Bone marrow T-cells are tumor-infiltrating T-cells in pediatric patients with acute leukemia and their phenotype reflects immune evasion of leukemic blasts. , 2019, , .		0
135	A Phase I Open Label Dose Escalation Study of MB-CART19.1 in Relapsed and Refractory CD19+ B Cell Malignancies, Interim Preliminary Results in Pediatric ALL, Adult ALL Including CLL Cohorts. Blood, 2021, 138, 3836-3836.	1.4	0
136	Clofarabine Significantly Increases Eradication of Minimal Residual Disease of B-Precursor ALL Compared to High-Dose Cytarabine in Randomized Trial Coall 08-09. Blood, 2020, 136, 21-21.	1.4	0